Clinical trials reveal that Remdesivir may be beneficial for COVID-19
Johns Hopkins Bloomberg School of Public Health compiled data suggests remdesivir as another potential treatment for covid-19, The New York Times reported Saturday.
The report also said that scientists have released the data from a study that prompted support of remdesivir as another potential treatment for Covid-19.
Frustrated scientists had waited weeks for the chance to review the evidence. “For God’s sake, this is a pandemic — we need some data,” says Judith Feinberg, vice chair of research at West Virginia University School of Medicine.
Published in the New England Journal of Medicine Friday evening, the numbers reinforce the findings that the drug shortens recovery time in hospitalized patients from 15 days to 11 days. But the researchers emphasize that while the results were generally positive, it’s not a wonder drug.
“Given high mortality despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is not likely to be sufficient,” they concluded.